NK1 receptor antagonist

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10399949
APP PUB NO 20190002414A1
SERIAL NO

15781925

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A problem of the present invention is to provide a new compound which has NK1 receptor antagonist activity, and thus is useful for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • KISSEI PHARMACEUTICAL CO., LTD,

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kobayashi, Masahiro Matsumoto, JP 425 3882
Miyagi, Takashi Azumino, JP 50 423
Nishimura, Toshihiro Azumino, JP 74 1138

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 3, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 3, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00